Clinical trial · no report yet · Phase 2
NCT03993249
Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy
- NCT03993249 ↗
- Unknown
- Hellenic GenitoUrinary Cancer Group
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy: a Phase II, Randomized Study
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Bladder Cancer
- Interventions
- Nivolumab; chemoradiotherapy
- Arms
- Chemoradiotherapy · Other
- Combination · Experimental
- Enrollment
- 78 (estimated)
- Primary outcomes
- Locoregional control rate
- Sponsor
- Hellenic GenitoUrinary Cancer Group
- Start
- May 28, 2019
- Primary completion
- Aug 2022 (estimated)
- Results posted
- No
- Registry record
- NCT03993249 · updated Mar 23, 2022